CLINICAL TRIALS PROFILE FOR FAZACLO ODT
✉ Email this page to a colleague
All Clinical Trials for FAZACLO ODT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00501618 ↗ | Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder | Completed | Azur Pharma, Inc | Phase 4 | 2006-11-01 | The purpose of this study is to obtain data on equivalence of generic clozapine to Fazaclo (orally disintegrating tablet). Generic clozapine is the most frequently used clozapine and such data is important for clinicians to have. |
| NCT00501618 ↗ | Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder | Completed | Manhattan Psychiatric Center | Phase 4 | 2006-11-01 | The purpose of this study is to obtain data on equivalence of generic clozapine to Fazaclo (orally disintegrating tablet). Generic clozapine is the most frequently used clozapine and such data is important for clinicians to have. |
| NCT00683891 ↗ | FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey | Completed | Azur Pharma, Inc | 1969-12-31 | AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or other atypical antipsychotics treatments. Another important clinical observation reported by doctors is a considerable reduction in hypersalivation when FazaClo administration is compared to other antipsychotic treatments. Based on the findings described above, and on the real need for effective and safer treatments for schizophrenia, AZUR Pharma has decided to design and conduct an observational study in a large number of patients taking FazaClo to prove the received clinical reports from physicians. Better understanding and evaluation of these beneficial findings are necessary to provide physicians information for improved treatment decision. | |
| NCT02286206 ↗ | Study of the Effect of Dosing on Clozapine Levels | Withdrawn | University of British Columbia | Phase 4 | 2015-01-01 | The objectives of this 15-day study are: 1. To compare steady-state trough plasma concentrations of clozapine and its metabolite norclozapine when given once daily and twice daily (at the same total daily dose) 2. To determine if frequency of clozapine administration has an effect on: 1. Symptoms of schizophrenia 2. Adverse effects of clozapine 3. Fasting blood glucose, lipids, creatinine, and urea 4. Weight and waist circumference |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FAZACLO ODT
Condition Name
Clinical Trial Locations for FAZACLO ODT
Trials by Country
Clinical Trial Progress for FAZACLO ODT
Clinical Trial Phase
Clinical Trial Sponsors for FAZACLO ODT
Sponsor Name
